International impact of external reference pricing: should national policy-makers care?

被引:11
|
作者
Fontrier, Anna-Maria [1 ,2 ]
Gill, Jennifer [1 ,2 ]
Kanavos, Panos [1 ,2 ]
机构
[1] London Sch Econ & Polit Sci, Dept Hlth Policy, Houghton St, London WC2A 2AE, England
[2] London Sch Econ & Polit Sci, LSE Hlth Med Technol Res Grp, Houghton St, London WC2A 2AE, England
来源
EUROPEAN JOURNAL OF HEALTH ECONOMICS | 2019年 / 20卷 / 08期
关键词
External reference pricing; Pharmaceutical pricing; Pharmaceutical policy; Systematic review; Regulation of pharmaceuticals; Expert consultation;
D O I
10.1007/s10198-019-01083-w
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background External reference pricing (ERP) is widely used to regulate drug prices. Although the literature has largely focused on the impact of ERP on a number of policy endpoints and its impact from a geographical perspective, a comparative study drawing on evidence from different settings does not exist to date. Methods A systematic literature review was conducted on pre-defined endpoints on the impact of ERP across countries, such as price stability, price convergence and launch delays. Expert consultation was undertaken to analyse whether or not the international implications of ERP are considered during its design. Results 46 studies were included in the analysis. Across countries, ERP may cause launch delays, price instability and lead to price convergence. However, these effects cannot be solely attributed to ERP, as there may be other factors at play, such as the size and the GDP of a country and other regulations in place, which can trigger these effects or reduce their effect. Nevertheless, the nature of ERP facilitates these unintended consequences and directly links them to it. Despite these cross-country implications being well known to decision-makers, they are not necessarily considered during the design of ERP. Conclusions As the effects of ERP as a stand alone policy are very difficult to isolate in the presence of other regulatory measures implemented within countries and the presence of other extrinsic factors across countries, our findings are inconclusive. Still, there is an unquestionable unmet need related to the design of ERP systems to attain a positive impact internationally.
引用
收藏
页码:1147 / 1164
页数:18
相关论文
共 50 条
  • [41] LONG-ACTING CONTRACEPTIVES - ETHICAL GUIDANCE FOR POLICY-MAKERS AND HEALTH-CARE PROVIDERS
    MOSKOWITZ, EH
    JENNINGS, B
    CALLAHAN, D
    HASTINGS CENTER REPORT, 1995, 25 (01) : S1 - S8
  • [42] Views of health care professionals and policy-makers on the use of surveillance data to combat antimicrobial resistance
    Al-Haboubi, Mustafa
    Trathen, Andrew
    Black, Nick
    Eastmure, Elizabeth
    Mays, Nicholas
    BMC PUBLIC HEALTH, 2020, 20 (01)
  • [43] Is patient-centred care for women a priority for policy-makers? Content analysis of government policies
    Anna R. Gagliardi
    Sheila Dunn
    Angel M. Foster
    Sherry L. Grace
    Nazilla Khanlou
    Donna E. Stewart
    Sharon E. Straus
    Health Research Policy and Systems, 18
  • [44] Views of health care professionals and policy-makers on the use of surveillance data to combat antimicrobial resistance
    Mustafa Al-Haboubi
    Andrew Trathen
    Nick Black
    Elizabeth Eastmure
    Nicholas Mays
    BMC Public Health, 20
  • [45] IMPACT OF INTERNATIONAL REFERENCE PRICING ON FIVE PRODUCTS IN THE USA
    De Cristofano, F.
    Barling, H.
    VALUE IN HEALTH, 2019, 22 : S299 - S299
  • [46] PROPOSED US INTERNATIONAL REFERENCE PRICING, POSSIBLE IMPACT
    Mycka, J.
    Lobb, W.
    Dellamano, R.
    Dalal, N.
    Pereira, E.
    Dellamano, L.
    VALUE IN HEALTH, 2020, 23 : S300 - S300
  • [47] PEOPLE, POLLS, AND POLICY-MAKERS - AMERICAN PUBLIC-OPINION AND NATIONAL-SECURITY - HINCKLEY,RH
    SHAPIRO, RY
    PUBLIC OPINION QUARTERLY, 1993, 57 (01) : 121 - 123
  • [48] Variations in external reference pricing implementation: does it matter for public policy?
    Jennifer Gill
    Anna-Maria Fontrier
    Dionysis Kyriopoulos
    Panos Kanavos
    The European Journal of Health Economics, 2019, 20 : 1375 - 1397
  • [49] ORPHAN DRUG PRICES IN EUROPE: IMPACT OF EXTERNAL REFERENCE PRICING
    Chachoua, L.
    Achour, L.
    Hanna, E.
    Borrisov, B.
    Toumi, M.
    VALUE IN HEALTH, 2018, 21 : S313 - S313
  • [50] Variations in external reference pricing implementation: does it matter for public policy?
    Gill, Jennifer
    Fontrier, Anna-Maria
    Kyriopoulos, Dionysis
    Kanavos, Panos
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2019, 20 (09): : 1375 - 1397